Switching to a once-daily bictegravir/lenacapavir (BIC/LEN) single-tablet regimen is generally well tolerated through 48 ...
At IDWeek 2026, Paul Sax, MD, and Cynthia Sears, MD, highlighted practice-changing developments bridging clinical infectious ...
Treatment-experienced patients with HIV and viremia achieve high virologic suppression with long-acting CAB/RPV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results